Literature DB >> 21962439

PDE1 isozymes, key regulators of pathological vascular remodeling.

Stefan Chan1, Chen Yan.   

Abstract

Pathological vascular remodeling is a hallmark of most vascular disorders such as atherosclerosis, postangioplasty restenosis, allograft vasculopathy, and pulmonary hypertension. Pathological vascular remodeling is a multi-cell-dependent process leading to detrimental changes of vessel structure and eventual vessel occlusion. Cyclic nucleotide signaling regulates a variety of vascular functions ranging from cell contractility to cell growth. Cyclic nucleotide phosphodiesterases (PDEs), a large family of structurally and functionally distinct isozymes, regulate cyclic nucleotide levels and compartmentalization through catalyzing their degradation reaction. Increasing evidence has suggested that one of the important mechanisms for specific cyclic nucleotide regulation is exerted through selective activation or inhibition of distinct PDE isozymes. This review summarizes the work done to characterize the role and therapeutic potential of PDE1 isozymes in pathological vascular remodeling.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21962439      PMCID: PMC3225597          DOI: 10.1016/j.coph.2011.09.002

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  52 in total

1.  Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.

Authors:  Stuart J Netherton; Donald H Maurice
Journal:  Mol Pharmacol       Date:  2004-10-08       Impact factor: 4.436

2.  Restoration of neuronal plasticity by a phosphodiesterase type 1 inhibitor in a model of fetal alcohol exposure.

Authors:  Alexandre E Medina; Thomas E Krahe; Ary S Ramoa
Journal:  J Neurosci       Date:  2006-01-18       Impact factor: 6.167

Review 3.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.

Authors:  J A Beavo
Journal:  Physiol Rev       Date:  1995-10       Impact factor: 37.312

4.  Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study.

Authors:  Géza Szilágyi; Zoltán Nagy; László Balkay; István Boros; Miklós Emri; Szabolcs Lehel; Teréz Márián; Tamás Molnár; Szabolcs Szakáll; Lajos Trón; Dániel Bereczki; László Csiba; István Fekete; Levente Kerényi; László Galuska; József Varga; Péter Bönöczk; Adám Vas; Balázs Gulyás
Journal:  J Neurol Sci       Date:  2005-01-08       Impact factor: 3.181

Review 5.  Inflammation and atherosclerosis.

Authors:  Peter Libby; Paul M Ridker; Attilio Maseri
Journal:  Circulation       Date:  2002-03-05       Impact factor: 29.690

6.  Selective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiation.

Authors:  Andrew T Bender; Cari L Ostenson; Edith H Wang; Joseph A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-29       Impact factor: 11.205

7.  Regulation of vascular endothelial barrier function by Epac, a cAMP-activated exchange factor for Rap GTPase.

Authors:  Xavier Cullere; Sunil K Shaw; Lorna Andersson; Junichi Hirahashi; Francis W Luscinskas; Tanya N Mayadas
Journal:  Blood       Date:  2004-09-16       Impact factor: 22.113

8.  cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling.

Authors:  Peter G Phillips; Lu Long; Martin R Wilkins; Nicholas W Morrell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2004-09-17       Impact factor: 5.464

9.  Expression of olfactory-type cyclic nucleotide-gated channel (CNGA2) in vascular tissues.

Authors:  Kwong-Tai Cheng; Franky Leung Chan; Yu Huang; Wing-Yee Chan; Xiaoqiang Yao
Journal:  Histochem Cell Biol       Date:  2003-11-15       Impact factor: 4.304

10.  Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors.

Authors:  Ralph Theo Schermuly; Christiane Inholte; Hossein Ardeschir Ghofrani; Henning Gall; Norbert Weissmann; Andreas Weidenbach; Werner Seeger; Friedrich Grimminger
Journal:  Respir Res       Date:  2005-07-20
View more
  22 in total

Review 1.  Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.

Authors:  Allen F Brooks; Lindsey R Drake; Megan N Stewart; Brian P Cary; Isaac M Jackson; Dale Mallette; Andrew V Mossine; Peter J H Scott
Journal:  Pharm Pat Anal       Date:  2015-12-16

Review 2.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

3.  Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP-signaling modules in T cells.

Authors:  Michael-Claude G Beltejar; Ho-Tak Lau; Martin G Golkowski; Shao-En Ong; Joseph A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-20       Impact factor: 11.205

4.  Discovery of novel PDE10 inhibitors by a robust homogeneous screening assay.

Authors:  Qun-yi Li; Ming-kai Xu; Gang Liu; Claus Tornby Christoffersen; Ming-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2013-04-22       Impact factor: 6.150

5.  PDE1A inhibition elicits cGMP-dependent relaxation of rat mesenteric arteries.

Authors:  Makhala Michell Khammy; Thomas Dalsgaard; Peter Hjørringgaard Larsen; Claus Tornby Christoffersen; Dorte Clausen; Lars Kyhn Rasmussen; Lasse Folkersen; Morten Grunnet; Jan Kehler; Christian Aalkjaer; Jacob Nielsen
Journal:  Br J Pharmacol       Date:  2017-10-15       Impact factor: 8.739

Review 6.  An update on vinpocetine: New discoveries and clinical implications.

Authors:  Yi-Shuai Zhang; Jian-Dong Li; Chen Yan
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

Review 7.  Transcriptional profiling of the ductus arteriosus: Comparison of rodent microarrays and human RNA sequencing.

Authors:  Michael T Yarboro; Matthew D Durbin; Jennifer L Herington; Elaine L Shelton; Tao Zhang; Cris G Ebby; Jason Z Stoller; Ronald I Clyman; Jeff Reese
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

8.  Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats.

Authors:  Morten Laursen; Lilliana Beck; Jan Kehler; Claus Tornby Christoffersen; Christoffer Bundgaard; Susie Mogensen; Tomas Joachim Mow; Estéfano Pinilla; Jakob Schöllhammer Knudsen; Elise Røge Hedegaard; Morten Grunnet; Ulf Simonsen
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739

Review 9.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

Review 10.  Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?

Authors:  Maria Gabriella Matera; Paola Rogliani; Luigino Calzetta; Mario Cazzola
Journal:  Drugs       Date:  2014-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.